Long-Term Data Shows AYVAKIT's Benefit
Blueprint Medicines, a Sanofi company, announced positive four-year data for its drug AYVAKIT. The PIONEER study shows the treatment provides sustained benefits and long-term safety for patients with indolent systemic mastocytosis. The data was part of 12 presentations at the 2026 AAAAI Annual Meeting, reinforcing the company's focus on the rare disease.
Indolent systemic mastocytosis (ISM) is a rare disease driven by a mutation in the KIT D816V gene in about 95% of cases. This mutation leads to an overproduction of mast cells, causing a wide range of debilitating symptoms like skin lesions, diarrhea, brain fog, and bone pain, which can significantly impair a patient's quality of life. The four-year PIONEER trial data for AYVAKIT (avapritinib) shows sustained and deep symptom control in patients with ISM. With a median treatment duration of 40 months, patients experienced a mean change from baseline in their total symptom score of -19.80 at 33 months and -20.43 at 39 months. These improvements were seen across all symptom areas, including skin, gastrointestinal, and neurocognitive domains. Beyond symptom relief, AYVAKIT demonstrated disease-modifying effects by improving bone health. In patients who underwent DXA scans, there were notable increases in bone mineral density in the lumbar spine and hip at both one and three years of treatment, irrespective of the use of other anti-osteoporosis therapies. The long-term safety profile of AYVAKIT remains favorable, supporting its use as a chronic treatment. After approximately 3.5 years of follow-up, the discontinuation rate due to treatment-related adverse events was low at just 3%. The most common side effects included edema, dizziness, and flushing, with the majority of these events being mild. AYVAKIT is a targeted therapy that works by selectively inhibiting the KIT D816V protein, which is the primary driver of the disease. Before its approval for ISM in May 2023, there were no approved therapies that addressed the underlying cause of the condition; treatments were primarily focused on managing symptoms. The long-term data also showed a significant reduction in the markers of mast cell burden. This includes a notable decrease in serum tryptase levels and the KIT D816V allele fraction in the blood, providing objective evidence of the drug's impact on the disease at a cellular level. In one specific example of symptom improvement, patients who experienced frequent diarrhea at the start of the study saw a median reduction of 65.6% in the frequency of these episodes after at least four years of treatment with AYVAKIT. This improvement in individual gastrointestinal symptoms often allowed for a decreased need for other supportive medications.
